HX017 / HanX Biopharma, Waterstone Hanxbio - LARVOL DELTA

Discovery of HX017, a novel NKG2A/CD94 mAb, for potential cancer immunotherapy (SITC 2023) - "Several NKG2A/CD94 blocking mAb (e. g. Monalizumab) are being tested in clinic, demonstrating preliminary antitumor activity in certain solid tumors including head and neck carcinoma (HNSCC) and non-small cell lung carcinoma (NSCLC). Finally, HX017 has good stability. Conclusions HX017 could potentially be developed as a promising candidate cancer immunotherapy, particularly in combination with other ICIs."

IO biomarker • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CD4 • CD8 • HLA-E • IL15 • KLRC1 • KLRD1 • PD-L1